Standard BioTools Inc.

Standard BioTools™ (Nasdaq:LAB), previously known as Fluidigm, is driven by a bold vision – Unleashing tools to accelerate breakthroughs in human health. 

Standard BioTools has an established portfolio of essential, standardised next-generation technologies that help biomedical researchers develop breakthroughs in human health faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes.

Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy.

Learn more at  standardbiotools.com or connect with us on Twitter, Facebook and LinkedIn.

Product hub: Uncover spatial biology secrets. Gain disease insights.

Application note: Hyperion+ imaging system

Translating complex, high-parameter immune data from clinical samples into actionable disease insights